+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastric Cancer - Pipeline Review, H1 2020

  • ID: 5024742
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 2197 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • BeiGene Ltd
  • eFFECTOR Therapeutics Inc
  • Immunomedics Inc
  • NeuClone Pty Ltd
  • Shanghai GeneChem Co Ltd
  • MORE
Gastric Cancer - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2020, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 16, 113, 169, 1, 15, 148, 27 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 9, 1, 8 and 4 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • BeiGene Ltd
  • eFFECTOR Therapeutics Inc
  • Immunomedics Inc
  • NeuClone Pty Ltd
  • Shanghai GeneChem Co Ltd
  • MORE
  • Introduction
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Gastric Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..8), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..9), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..7), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..8), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..9), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Gastric Cancer - Pipeline by 3SBio Inc, H1 2020
  • Gastric Cancer - Pipeline by AbbVie Inc, H1 2020
  • Gastric Cancer - Pipeline by AbClon Inc, H1 2020
  • Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2020
  • Gastric Cancer - Pipeline by Abion Inc, H1 2020
  • Gastric Cancer - Pipeline by ABL Bio Inc, H1 2020
  • Gastric Cancer - Pipeline by Abpro Corp, H1 2020
  • Gastric Cancer - Pipeline by Acepodia Biotech Inc, H1 2020
List of Figures
  • Number of Products under Development for Gastric Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • AbbVie Inc
  • AbClon Inc
  • AbGenomics International Inc
  • Abion Inc
  • ABL Bio Inc
  • Abpro Corp
  • Acepodia Biotech Inc
  • Acrotech Biopharma LLC
  • AD Pharmaceuticals Co Ltd
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Affimed GmbH
  • AffyImmune Therapeutics Inc
  • AIMM Therapeutics BV
  • Akeso Biopharma Inc
  • Alkermes Plc
  • Alligator Bioscience AB
  • Alphamab Oncology
  • Alteogen Inc
  • Ambrx Inc
  • amcure GmbH
  • Amgen Inc
  • Andes Biotechnologies
  • Anew Oncology Inc
  • Antapodia Therapeutics Inc
  • Antikor Biopharma Ltd
  • Apollomics Inc
  • Apotex Inc
  • Arbele Ltd
  • Argonaut Therapeutics Ltd
  • Arromax Pharmatech Co Ltd
  • Asana BioSciences LLC
  • Ascelia Pharma AB
  • Ascenta Therapeutics Inc
  • AskAt Inc
  • Aslan Pharmaceuticals Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • Aurora BioPharma Inc
  • Basilea Pharmaceutica Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing BGI-GBI Biotech Co Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Beijing Mabworks Biotech Co Ltd
  • Beijing Syngentech Co Ltd
  • Bellicum Pharmaceuticals Inc
  • Benhealth Biopharmaceutical (Shenzhen) Co Ltd
  • Betta Pharmaceuticals Co Ltd
  • Bio-Thera Solutions Ltd
  • BioEclipse Therapeutics Inc
  • BioIntegrator Ltd
  • BioLineRx Ltd
  • BioMed Valley Discoveries Inc
  • Biomunex Pharmaceuticals
  • BioNTech SE
  • Biosion Inc
  • Biotecnol Ltd
  • BJ Bioscience Inc
  • Bliss Biopharmaceutical (Hangzhou) Co Ltd
  • Boehringer Ingelheim International GmbH
  • Bold Therapeutics Inc
  • Bolt Biotherapeutics Inc
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • CalyGene Biotechnology Inc
  • Camel-IDS NV
  • Cancer Prevention Pharmaceuticals Inc
  • CARsgen Therapeutics Ltd
  • CAS-Lamvac Biotech Co Ltd
  • Catalent Inc
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Cellid Co Ltd
  • Cellivery Therapeutics Inc
  • Cello Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Celon Pharma SA
  • Cend Therapeutics Inc
  • Checkmate Pharmaceuticals Inc
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Chipscreen Biosciences Ltd
  • Chugai Pharmaceutical Co Ltd
  • Cloaked Therapeutics LLC
  • CMG Pharmaceutical Co Ltd
  • Coherent Biopharma
  • Convalife
  • CSPC Pharmaceutical Group Ltd
  • CStone Pharmaceuticals Co Ltd
  • Cumberland Pharmaceuticals Inc
  • Curegenix Inc
  • CureLab Oncology Inc
  • CureMeta LLC
  • Cynvec LLC
  • Cytocom Inc
  • Cytodyn Inc
  • CytoMed Therapeutics Pte Ltd
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Delta-Fly Pharma Inc
  • DiNonA Inc
  • DM Bio Ltd
  • Dr. Reddy's Laboratories Ltd
  • Eddingpharm Inc
  • eFFECTOR Therapeutics Inc
  • EirGenix Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EOS Biosciences Inc
  • ERYTECH Pharma SA
  • Esperance Pharmaceuticals Inc
  • Eutilex Co Ltd
  • Exelixis Inc
  • EXUMA Biotech Inc
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics Inc
  • Five Prime Therapeutics Inc
  • Frost Biologic Inc
  • G+FLAS Life Sciences Inc
  • GEMoaB Monoclonals GmbH
  • Geneius Biotechnology Inc
  • Genentech Inc
  • GeneScience Pharmaceuticals Co Ltd
  • Genmab AS
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GLG Pharma SA
  • GlycoNex Inc
  • Glycotope GmbH
  • Good T Cells Inc
  • Gossamer Bio Inc
  • Green Cross LabCell Corp
  • Grid Therapeutics LLC
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hangzhou DAC Biotech Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Harbour BioMed
  • Hengenix Biotech Inc
  • HengRui YuanZheng Bio-Technology Co Ltd
  • Hope Biosciences Inc
  • Horizon Therapeutics PLC
  • Hummingbird Bioscience Pte Ltd
  • Hutchison MediPharma Ltd
  • I-Mab Biopharma Co Ltd
  • Ichnos Sciences Inc
  • Igem Therapeutics Ltd
  • Ildong Pharmaceutical Co Ltd
  • ImCheck Therapeutics SAS
  • Immunicum AB
  • ImmunityBio Inc
  • Immunocore Ltd
  • Immunomedics Inc
  • Immunomet Therapeutics Inc
  • Immunomic Therapeutics Inc
  • Imugene Ltd
  • Incyte Corp
  • Inhibrx Inc
  • Innovative Cellular Therapeutics Co Ltd
  • Innovent Biologics Inc
  • Inovio Pharmaceuticals Inc
  • Intra-Immusg Pvt Ltd
  • InxMed Shanghai Co Ltd
  • Ipsen SA
  • Jeil Pharmaceutical Co Ltd
  • JHL Biotech Inc
  • Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Jiuzhitang Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • JW Pharmaceutical Corp
  • Karyopharm Therapeutics Inc
  • KLUS Pharma Inc
  • Komipharm International Co Ltd
  • Konruns Pharmaceutical Co Ltd
  • Kringle Pharma Inc
  • Kupffer Biotherapeutics Inc
  • Kymab Ltd
  • Kyowa Kirin Co Ltd
  • LATITUDE Pharmaceuticals Inc
  • LegoChem Biosciences Inc
  • Lepu Medical Technology (Beijing) Co Ltd
  • Leukocare AG
  • Luye Pharma Group Ltd
  • Mabpharm Ltd
  • MacroGenics Inc
  • MaxiVAX SA
  • MBQ Pharma Inc
  • MedAbome Inc
  • Meditope Biosciences Inc
  • MedPacto Inc
  • Merck & Co Inc
  • Merck KGaA
  • Mereo Biopharma Group Plc
  • Merus NV
  • Metagone Biotech Inc
  • Metis Precision Medicine
  • Millennium Pharmaceuticals Inc
  • Mitsubishi Tanabe Pharma Corp
  • Moderna Inc
  • Molecular Partners AG
  • Molecular Templates Inc
  • Moleculin Biotech LLC
  • Multitude therapeutics Inc
  • Mustang Bio Inc
  • Mycenax Biotech Inc
  • Nanjing Iaso Biotherapeutics Co Ltd
  • Nanjing Legend Biotech Co Ltd
  • Nanjing Sanhome Pharmaceutical Co Ltd
  • Nanjing Tianyi Bioscience Co Ltd
  • NanoCarrier Co Ltd
  • NeuClone Pty Ltd
  • NewBio Therapeutics Inc
  • NGM Biopharmaceuticals Inc
  • Nouscom AG
  • Novartis AG
  • Novonco Pharmaceuticals Inc
  • OBI Pharma Inc
  • Ocellaris Pharma Inc
  • Ona Therapeutics SL
  • OncoImmune Inc
  • Oncologie Inc
  • Oncolys BioPharma Inc
  • OncoSynergy Inc
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Opsona Therapeutics Ltd
  • Orano Med LLC
  • Oxford BioTherapeutics Ltd
  • Patrys Ltd
  • Peptron Inc
  • PersonGen Biomedicine Suzhou Co Ltd
  • Pfizer Inc
  • Phanes Therapeutics Inc
  • Pharma Mar SA
  • Pharmapraxis
  • Phosplatin Therapeutics LLC
  • Pieris Pharmaceuticals Inc
  • Plus Therapeutics Inc
  • PNB Vesper Life Science Pvt Ltd
  • Prescient Therapeutics Ltd
  • Prestige BioPharma Pte Ltd
  • ProLynx LLC
  • Protheragen Inc
  • Puma Biotechnology Inc
  • QED Therapeutics Inc
  • Qilu Puget Sound Biotherapeutics Corp
  • Rakuten Medical Inc
  • RAPT Therapeutics Inc
  • RaQualia Pharma Inc
  • Redx Pharma Plc
  • RemeGen Ltd
  • Rhizen Pharmaceuticals SA
  • Richter Gedeon Nyrt
  • RUS Pharmtech
  • Samumed LLC
  • Samyang Holdings Corp
  • Sanofi
  • Scancell Holdings Plc
  • Seattle Genetics Inc
  • SELLAS Life Sciences Group Inc
  • Shanghai Biomed-Union Biotechnology Co Ltd
  • Shanghai Bioray Laboratory Inc
  • Shanghai GeneChem Co Ltd
  • Shanghai Haihe Biopharma Co Ltd
  • Shanghai Henlius Biotech Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Keqi Pharmaceutical Technology Co Ltd
  • Shanghai Miracogen Inc
  • Shanghai Pharmaceutical Group Co Ltd
  • Shaperon Inc
  • Shenyang Dongxing Pharmaceutical Co Ltd
  • Shenzhen BinDeBio Ltd
  • Shenzhen Fapon Biopharma Inc
  • Shenzhen Hornetcorn Bio-technology Company Ltd
  • Shenzhen NeoCura Biotechnology Corp
  • Shionogi & Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sillajen Biotherapeutics
  • Simcere Pharmaceutical Group
  • Sino Biopharmaceutical Ltd
  • Sinocelltech Ltd
  • SN BioScience
  • Sorrento Therapeutics Inc
  • Sotio AS
  • Spring Bank Pharmaceuticals Inc
  • Stcube Inc
  • Stemirna Therapeutics Inc
  • StemMed Ltd
  • Suntec Medical (Taiwan) Inc
  • Supratek Pharma Inc
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • SynCore Biotechnology Co Ltd
  • Synthon Holdings BV
  • T-Cure Bioscience Inc
  • Taiho Oncology Inc
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Takis Srl
  • Tarveda Therapeutics Inc
  • Tasly Pharmaceutical Group Co Ltd
  • Tempest Therapeutics Inc
  • Tessa Therapeutics Pte Ltd
  • Themis Bioscience GmbH
  • Tonix Pharmaceuticals Holding Corp
  • Toray Industries Inc
  • TOT Biopharm Co Ltd
  • Treos Bio Ltd
  • Trio Medicines Ltd
  • Triumvira Immunologics Inc
  • Turning Point Therapeutics Inc
  • Turnstone Biologics Inc
  • Tvardi Therapeutics Inc
  • Tyg Oncology Ltd
  • Ube Industries Ltd
  • United BioPharma Inc
  • Vaxon Biotech
  • Vedanta Biosciences Inc
  • Venus Remedies Ltd
  • Viracta Therapeutics Inc
  • Viral Gene Inc
  • Well Marker Bio Co Ltd
  • Wellmarker Bio Co Ltd
  • Wuhan Binhui Biotechnology Co Ltd
  • Wuhan YZY Biopharma Co Ltd
  • Xcovery Holding Co LLC
  • Xencor Inc
  • Xiangxue Life Sciences
  • XuanZhu Pharma Co Ltd
  • Zai Lab Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Zhejiang Jianfeng Group Company Ltd
  • Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
Adroll
adroll